Royalty Pharma ups Elan offer to $12.50
UPDATE: Royalty Pharma is to increase its offer price for Irish-headquartered Elan to $12.50 per share in cash. Elan said it will assess the new bid.
Royalty Pharma is to increase its offer price for Irish-headquartered Elan to $12.50 per share in cash.
The increased offer, up from the $11.25 a share rejected by Elan last month, is fully financed, cash confirmed and not conditional on due diligence, the company said.
Royalty said that its new offer values Elan’s Tysabri royalty at $4.6 billion, a 42 per cent premium to the $3.25 billion at which Elan sold approximately half of its interest in...
Subscribe from just €1 for the first month!
With any subscription you will have access to
Unlimited multi-device access to our iPad, iPhone and Android Apps
Unlimited access to our eReader library
Exclusive daily insight and opinion seven days a week
Create alerts to never miss a subject that matters to you
Get access to exclusive offers for subscribers on gifts and experiences
Get content from Business Post, Business Post Magazines, Connected, Tatler and Food & Wine